Kelly R Reveles1, Mary Jo V Pugh2, Kenneth A Lawson3, Eric M Mortensen4, Jim M Koeller5, Jacqueline R Argamany5, Christopher R Frei6. 1. College of Pharmacy, The University of Texas at Austin, Austin, TX; Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, TX; South Texas Veterans Health Care System, San Antonio, TX. Electronic address: kdaniels46@utexas.edu. 2. South Texas Veterans Health Care System, San Antonio, TX; Department of Epidemiology and Biostatistics, UT Health San Antonio, San Antonio, TX. 3. College of Pharmacy, The University of Texas at Austin, Austin, TX. 4. Department of Internal Medicine and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX; Department of General Internal Medicine, VA North Texas Health Care System, Dallas, TX. 5. College of Pharmacy, The University of Texas at Austin, Austin, TX; Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, TX. 6. College of Pharmacy, The University of Texas at Austin, Austin, TX; Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, TX; South Texas Veterans Health Care System, San Antonio, TX.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) occurs frequently in inpatient settings; however, community-onset cases have been reported more frequently in recent years. This study evaluated hospital-onset and community-onset CDI in the national Veterans Health Administration (VHA) population over a 12-year period. METHODS: This was a retrospective cohort study of all adult VHA beneficiaries with CDI between October 1, 2002, and September 30, 2014. Data were obtained from the Veterans Affairs Informatics and Computing Infrastructure. CDI was categorized into community-associated CDI (CA-CDI); community-onset, health care facility-associated CDI; and health care facility-onset CDI (HCFO-CDI). Each type was described longitudinally and was assessed as an independent risk factor for health outcomes using multivariable logistic regression. RESULTS: Overall, 30,326 patients with a first CDI episode were included. HCFO-CDI was the predominant type (60.2%), followed by CO-HCFA-CDI (20.6%) and CA-CDI (19.2%). The proportion of patients with HCFO-CDI decreased from 73.5% during fiscal year 2003 to 53.2% during fiscal year 2014, whereas CA-CDI increased from 8.3% to 26.7%. HCFO-CDI was a positive predictor of severe CDI (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.59-1.84) and 30-day mortality (OR, 1.46; 95% CI, 1.32-1.61), but a negative predictor of 60-day recurrence (OR, 0.41; 95% CI, 0.37-0.46). CONCLUSIONS: HCFO-CDI was the predominant CDI type. The proportion of patients with CA-CDI increased and HCFO-CDI decreased in recent years. Patients with HCFO-CDI experienced higher rates of severe CDI and mortality.
BACKGROUND:Clostridium difficileinfection (CDI) occurs frequently in inpatient settings; however, community-onset cases have been reported more frequently in recent years. This study evaluated hospital-onset and community-onset CDI in the national Veterans Health Administration (VHA) population over a 12-year period. METHODS: This was a retrospective cohort study of all adult VHA beneficiaries with CDI between October 1, 2002, and September 30, 2014. Data were obtained from the Veterans Affairs Informatics and Computing Infrastructure. CDI was categorized into community-associated CDI (CA-CDI); community-onset, health care facility-associated CDI; and health care facility-onset CDI (HCFO-CDI). Each type was described longitudinally and was assessed as an independent risk factor for health outcomes using multivariable logistic regression. RESULTS: Overall, 30,326 patients with a first CDI episode were included. HCFO-CDI was the predominant type (60.2%), followed by CO-HCFA-CDI (20.6%) and CA-CDI (19.2%). The proportion of patients with HCFO-CDI decreased from 73.5% during fiscal year 2003 to 53.2% during fiscal year 2014, whereas CA-CDI increased from 8.3% to 26.7%. HCFO-CDI was a positive predictor of severe CDI (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.59-1.84) and 30-day mortality (OR, 1.46; 95% CI, 1.32-1.61), but a negative predictor of 60-day recurrence (OR, 0.41; 95% CI, 0.37-0.46). CONCLUSIONS:HCFO-CDI was the predominant CDI type. The proportion of patients with CA-CDI increased and HCFO-CDI decreased in recent years. Patients with HCFO-CDI experienced higher rates of severe CDI and mortality.
Authors: Jerry W Simecka; Kimberly G Fulda; Mark Pulse; Joon-Hak Lee; John Vitucci; Phung Nguyen; Patricia Taylor; Frank Filipetto; Anna M Espinoza; Sushma Sharma Journal: PLoS One Date: 2019-08-15 Impact factor: 3.240
Authors: M J T Crobach; D W Notermans; C Harmanus; I M J G Sanders; S C De Greeff; E J Kuijper Journal: Open Forum Infect Dis Date: 2019-11-26 Impact factor: 3.835
Authors: Shinsmon Jose; Anindita Mukherjee; Olivia Horrigan; Kenneth D R Setchell; Wujuan Zhang; Maria E Moreno-Fernandez; Heidi Andersen; Divya Sharma; David B Haslam; Senad Divanovic; Rajat Madan Journal: Mucosal Immunol Date: 2020-08-18 Impact factor: 7.313